Unveiling 5 Analyst Insights On Arcus Biosciences
Portfolio Pulse from Benzinga Insights
Five analysts have recently provided ratings for Arcus Biosciences (NYSE:RCUS), with a mix of 'Somewhat Bullish' and 'Indifferent' sentiments. The average 12-month price target is $26.4, a decrease from previous estimates. Analysts have varied in their ratings, with some maintaining 'Outperform' and others adjusting to 'Neutral'. Arcus Biosciences, a clinical-stage biopharmaceutical company, has shown revenue growth but lags behind industry peers. The company's financial health is mixed, with strong net margins and ROE but challenges in asset utilization.
October 21, 2024 | 2:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Arcus Biosciences has received mixed analyst ratings, with a decrease in the average price target to $26.4. The company's financial health shows strong net margins and ROE but challenges in asset utilization.
The mixed analyst ratings and decrease in the average price target suggest a neutral short-term impact on Arcus Biosciences' stock price. The company's financial health indicators are mixed, with strong net margins and ROE but challenges in asset utilization, which may influence investor sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100